| Expression of monocarboxylate transporter 4 in pancreatic cancer and its prognostic value |
| Received:September 03, 2020 Revised:September 17, 2020 Click here to download the full text |
| Citation of this paper:XU Shuai-shuai,LI Shuo,LI Hao,YE Long-yun,LIU Liang,YU Xian-jun,XU Hua-xiang.Expression of monocarboxylate transporter 4 in pancreatic cancer and its prognostic value[J].Chinese Journal of Clinical Medicine,2020,27(5):730-734 |
| Hits: 1469 |
| Download times: 546 |
| Author Name | Affiliation | E-mail | | XU Shuai-shuai | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | LI Shuo | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | LI Hao | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | YE Long-yun | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | LIU Liang | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | YU Xian-jun | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | | | XU Hua-xiang | Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Institute of Pancreatic Cancer, Shanghai 200032, China | xuhuaxiang@fudanpci.org |
|
| Abstract:Objective: To determine the expression of monocarboxylate transporter 4 (MCT4) in pancreatic cancer tissue and its prognostic value after radical resection. Methods: The clinical data of 379 pancreatic cancer patients who underwent radical resection at Pancreatic Surgery of Fudan University Shanghai Cancer Center from February 2010 to June 2014 were retrospectively included in the study. The expression of MCT4 was tested with immunohistochemical staining and its relationship with clinicopathological characteristics of patients was investigated. Kaplan-Meier survival curve and multivariate Cox regression analysis were applied to evaluate the prognostic value of MCT4 expression. Results: Patients with positive expression of MCT4 protein were prone to have larger tumor size (P=0.004), greater lymph node metastasis (P=0.005), and higher TNM stage (P=0.011). The median overall survival (OS, 12.4 months) time and recurrence-free survival (RFS, 7.3 months) time of patients with positive expression of MCT4 were significantly shorter than those of patients with negative expression of MCT4 (21.3 months, P<0.001; 11.4 months, P<0.001). Multivariate Cox regression analysis results showed that the positive expression of MCT4 was an independent predictor of shorter OS (hazard ratio=1.814, 95% confidence interval 1.433-2.296, P<0.001) and RFS (hazard ratio=1.648, 95% confidence interval 1.319-2.059, P<0.001) in pancreatic cancer patients after radical resection. Conclusions: The positive expression of MCT4 is an independent prognostic factor for pancreatic cancer patients after radical resection, and might be a potential marker for the selection and treatment of patients with high recurrence risk. |
| keywords:pancreatic cancer monocarboxylate transporter 4 prediction survival time |
| HTML View Full Text View/Add Comment Download reader |
|
|
|